Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains

MRSA 和 VISA 菌株中的抗生素耐药基因和耐药表型

基本信息

  • 批准号:
    8645580
  • 负责人:
  • 金额:
    $ 56.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-03-01 至 2016-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): MRSA and VISA strains continue to present serious challenge to the therapy of staphylococcal disease. Highly virulent and epidemic lineages have emerged among community acquired MRSA and treatment failure during vancomycin therapy continues to be reported in the clinical literature. As to the scientific challenges presented by drug resistant S. aureus: while several critical genetic determinants of the resistance mechanisms have been identified, the path leading from the resistant genes to the antibiotic resistant phenotype has remained an enigma in both MRSA and VISA strains. All clinical isolates of MRSA carry the same mecA gene encoding for the low antibiotic affinity protein PBP2a. Nevertheless, individual MRSA strains exhibit a vast range of oxacillin MIC values which can spread from a few micrograms up to the milligram range. Furthermore, the majority of MRSA isolates show a peculiar - heterogeneous - phenotype: such strains produce cultures in which the great majority of cells (99-99.9%) exhibit very low MIC values but the same cultures also contain one or more sub-populations of highly resistant bacteria which are present with low and unique frequencies. Besides presenting an intriguing scientific puzzle the phenomenon of hetero resistance may have important clinical implications as well, since selection of the highly resistant subpopulations in vivo may jeopardize the success of therapy. The mechanism by which these complex MRSA phenotypes are generated from the same mecA determinant is unknown. Similarly, genetic determinants associated with the acquisition of VISA type vancomycin resistance has been determined recently by full genome sequencing but the mechanism by which the increased vancomycin MIC value and the large number of phenotypic alterations are generated from the 33 specific mutations identified in the sequenced VISA strain JH9 [2] - remains to be determined. Thus, the common question posed for both the MRSA and VISA mechanisms in the new research program is this: how does one go from a resistance gene to the resistant phenotype? The studies in the new research program are organized into four major foci of activity. Project A. Genetic determinants of high level antibiotic resistance in heteroresistant MRSA clones. Project B. Genetic and environmental factors defining the antibiotic resistant phenotype in MRSA. Project C. Pathways of cell wall synthesis and antibiotic resistance level in MRSA. Project D. Genetic pathways to decreased vancomycin susceptibility.
描述(由申请方提供):MRSA和VISA菌株继续对葡萄球菌疾病的治疗提出严重挑战。在社区获得性MRSA中出现了高毒力和流行性谱系,临床文献中继续报告万古霉素治疗失败。对于耐药沙门氏菌所带来的科学挑战,金黄色:虽然已经鉴定了耐药机制的几个关键遗传决定因子,但是在MRSA和VISA菌株中,从耐药基因到抗生素耐药表型的途径仍然是个谜。 MRSA的所有临床分离株携带编码低抗生素亲和力蛋白PBP 2a的相同mecA基因。然而,个别MRSA菌株表现出广泛的苯唑西林MIC值范围,其可以从几微克扩展到毫克范围。此外,大多数MRSA分离株显示出独特的异质表型:这些菌株产生的培养物中,绝大多数细胞(99-99.9%)表现出非常低的MIC值,但相同的培养物还含有一个或多个以低且独特的频率存在的高度耐药细菌亚群。除了提出一个有趣的科学难题,异质耐药现象也可能具有重要的临床意义,因为体内高耐药亚群的选择可能危及治疗的成功。这些复杂MRSA表型由相同mecA决定子产生的机制尚不清楚。同样,最近通过全基因组测序确定了与获得VISA型万古霉素耐药性相关的遗传决定因素,但VISA菌株JH 9 [2]中鉴定的33种特异性突变产生万古霉素MIC值增加和大量表型改变的机制仍有待确定。因此,在新的研究计划中,MRSA和VISA机制的共同问题是:如何从耐药基因到耐药表型?新研究计划中的研究分为四个主要活动重点。项目A.异源耐药MRSA克隆中高水平抗生素耐药性的遗传决定因素。项目B。遗传和环境因素定义MRSA的抗生素耐药表型。C项目耐甲氧西林金黄色葡萄球菌细胞壁合成途径与耐药水平。D项目万古霉素敏感性降低的遗传途径。

项目成果

期刊论文数量(35)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The mechanism of heterogeneous beta-lactam resistance in MRSA: key role of the stringent stress response.
  • DOI:
    10.1371/journal.pone.0082814
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Kim C;Mwangi M;Chung M;Milheiriço C;de Lencastre H;Tomasz A
  • 通讯作者:
    Tomasz A
Properties of a novel PBP2A protein homolog from Staphylococcus aureus strain LGA251 and its contribution to the β-lactam-resistant phenotype.
  • DOI:
    10.1074/jbc.m112.395962
  • 发表时间:
    2012-10-26
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kim C;Milheiriço C;Gardete S;Holmes MA;Holden MT;de Lencastre H;Tomasz A
  • 通讯作者:
    Tomasz A
Evidence for the evolutionary steps leading to mecA-mediated β-lactam resistance in staphylococci.
  • DOI:
    10.1371/journal.pgen.1006674
  • 发表时间:
    2017-04
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
    Rolo J;Worning P;Boye Nielsen J;Sobral R;Bowden R;Bouchami O;Damborg P;Guardabassi L;Perreten V;Westh H;Tomasz A;de Lencastre H;Miragaia M
  • 通讯作者:
    Miragaia M
Methicillin-resistance in Staphylococcus aureus is not affected by the overexpression in trans of the mecA gene repressor: a surprising observation.
  • DOI:
    10.1371/journal.pone.0023287
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Oliveira DC;de Lencastre H
  • 通讯作者:
    de Lencastre H
Cocrystal structures of diaminopimelate decarboxylase: mechanism, evolution, and inhibition of an antibiotic resistance accessory factor.
  • DOI:
    10.1016/s0969-2126(02)00880-8
  • 发表时间:
    2002-11
  • 期刊:
  • 影响因子:
    5.7
  • 作者:
    S. Ray;J. Bonanno;J. Bonanno;K. Rajashankar;M. G. Pinho;G. He;G. He;H. Lencastre;A. Tomasz;Stephen K. Burley;Stephen K. Burley
  • 通讯作者:
    S. Ray;J. Bonanno;J. Bonanno;K. Rajashankar;M. G. Pinho;G. He;G. He;H. Lencastre;A. Tomasz;Stephen K. Burley;Stephen K. Burley
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALEXANDER TOMASZ其他文献

ALEXANDER TOMASZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALEXANDER TOMASZ', 18)}}的其他基金

S.AUREUS CELL WALLS AND DRUG RESISTANCE IN MRSA AND VRSA
金黄色葡萄球菌细胞壁与 MRSA 和 VRSA 的耐药性
  • 批准号:
    6511030
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains
MRSA 和 VISA 菌株中的抗生素耐药基因和耐药表型
  • 批准号:
    8260491
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Evolution and acquistion of drug resistance in MRSA
MRSA耐药性的进化和获得
  • 批准号:
    7046876
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains
MRSA 和 VISA 菌株中的抗生素耐药基因和耐药表型
  • 批准号:
    8063919
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains
MRSA 和 VISA 菌株中的抗生素耐药基因和耐药表型
  • 批准号:
    7987209
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Evolution and acquistion of drug resistance in MRSA
MRSA耐药性的进化和获得
  • 批准号:
    7569522
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
S.AUREUS CELL WALLS AND DRUG RESISTANCE IN MRSA AND VRSA
金黄色葡萄球菌细胞壁与 MRSA 和 VRSA 的耐药性
  • 批准号:
    6126568
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains
MRSA 和 VISA 菌株中的抗生素耐药基因和耐药表型
  • 批准号:
    8452718
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Evolution and acquistion of drug resistance in MRSA
MRSA耐药性的进化和获得
  • 批准号:
    7337996
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:
Evolution and acquistion of drug resistance in MRSA
MRSA耐药性的进化和获得
  • 批准号:
    7156971
  • 财政年份:
    2000
  • 资助金额:
    $ 56.94万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.94万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 56.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
    Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
    Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 56.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了